Ignite Creation Date:
2024-05-06 @ 7:18 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02506023
Status:
COMPLETED
Last Update Posted:
2018-07-16
First Post:
2015-07-21
Brief Title:
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP Desmopressin
Detailed Description:
DDAVP Desmopressin is commonly used in the treatment of persons with bleeding disorders such as hemophilia von Willebrand disease or qualitative platelet disorders to help them clot better The investigator wants to assess the increase in the subjects clotting factors in response to intravenous DDAVP Desmopressin and the levels of these internal clotting factors will be measured at different times after the medication is given The investigator will compare the response to DDAVP Desmopressin in adult hemophilia A carriers to women with a diagnosis of qualitative platelet dysfunction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None